{"id":"NCT00655356","sponsor":"Castle Creek Biosciences, LLC.","briefTitle":"Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-07","completion":"2009-05","firstPosted":"2008-04-09","resultsPosted":"2012-03-13","lastUpdate":"2012-03-13"},"enrollment":218,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bilateral Nasolabial Fold Wrinkles"],"interventions":[{"type":"BIOLOGICAL","name":"Autologous Human Fibroblasts (azficel-T)","otherNames":["LAVIV"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.","primaryOutcome":{"measure":"Subject Wrinkle Assessment Responders","timeFrame":"Baseline (prior to first treatment) and 6 months post final treatment","effectByArm":[{"arm":"Autologous Fibroblasts","deltaMin":50,"sd":null},{"arm":"Placebo","deltaMin":19,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.00001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":98},"commonTop":["Injection site haemorrhage","Injection site erythema","Injection site bruising","Upper respiratory tract infection"]}}